Torrent Pharmaceuticals share news, announcements and annual reports
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Torrent Pharmaceuticals Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994 on BSE, Nov 2002 on NSE
Last close ₹4,613.40up ₹33.40 (0.73%)BSE ₹4,635.15
Share price at the NSE close on 30 Oct 2026. Previous close ₹4,580.00.
30 Oct: open ₹4,560.00, high ₹4,672.00, low ₹4,532.00
52-week range of traded prices to 30 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,75,479 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 82.62
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.82%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.76
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,36,64564.6% delivered
Torrent Pharmaceuticals board meetings
111 filed, newest first. Page 3 of 3.
Jul 2009
15 Jul · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis of the Company as per clause 41 of the Listing Agreement for the quarter ended on June 30, 2009.
May 2009
5 May · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2009 and recommendation of dividend for the financial year 2008-09.
Jan 2009
19 Jan · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on December 31, 2008.
Oct 2008
14 Oct · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2008.
Apr 2008
24 Apr · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2008 and dividend for 2007-08.
Jan 2008
24 Jan · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on December 31, 2007.
Oct 2007
12 Oct · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2007.
Jul 2007
19 Jul · Board meeting
To consider, inter alia, Audited Financial Results of the Company for the quarter ended on June 30, 2007.
May 2007
9 May · Board meeting
To consider, interalia, the Audited Financial Results of the Company for the year ended on March 31, 2007.
Mar 2007
8 Mar · Board meeting
Inter alia, to consider declaration of Interim Dividend for the year 2006-07. Further, the Company has fixed March 26, 2007 as the Record date for the purpose of payment of said Interim Dividend, if declared and the payout of the said Interim Dividend if declared will be on & from March 30, 2007.
Jan 2007
12 Jan · Board meeting
To consider, inter alia, Audited Financial Results of the Company for the quarter ended on December 31, 2006.